Old Web
English
Sign In
Acemap
>
authorDetail
>
Chengxing Lu
Chengxing Lu
Novartis
Physical therapy
Medicine
Indacaterol
Exacerbation
COPD
4
Papers
113
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
INSTEAD: Randomized switch trial of indacaterol and salmeterol/fluticasone combination (SFC) in moderate COPD: Symptoms results
2015
European Respiratory Journal
Andrea Rossi
Thys Van Der Molen
Ricardo del Olmo
Alberto Papi
Luis Wehbe
Matthew Quinn
Chengxing Lu
David Young
Ray Cameron
Pablo Altman
Show All
Source
Cite
Save
Citations (1)
Late-breaking abstract: Phase 2a randomized placebo-controlled trial of the oral prostaglandin D2 receptor (DP2/ CRTh2) antagonist QAW039 in eosinophilic asthma
2014
European Respiratory Journal
Sherif Gonem
Rachid Berair
Amisha Singapuri
Ruth Hartley
Marie Laurencin
Gerald D. Bacher
Chengxing Lu
Bjoern Holzhauer
Michelle Bourne
Vijay Mistry
Ian D. Pavord
Adel Mansur
Andrew J. Wardlaw
Salman Siddiqui
Richard Kay
Christopher E. Brightling
Show All
Source
Cite
Save
Citations (8)
INSTEAD: a randomised switch trial of indacaterol versus salmeterol/fluticasone in moderate COPD
2014
European Respiratory Journal
Andrea Rossi
Thys Van Der Molen
Ricardo del Olmo
Alberto Papi
Luis Wehbe
Matthew Quinn
Chengxing Lu
David Young
Ray Cameron
Enrica Bucchioni
Pablo Altman
Show All
Source
Cite
Save
Citations (104)
S103 No Loss In Efficacy Following Switch From Salmeterol/fluticasone Combination To Indacaterol Monotherapy In Patients With Moderate Copd: The Instead Study
2014
Thorax
Andrea Rossi
Thys Van Der Molen
Ricardo del Olmo
Alberto Papi
Luis Webhe
Matthew Quinn
Chengxing Lu
David Young
Ray Cameron
Enrica Bucchioni
Pablo Altman
Show All
Source
Cite
Save
Citations (0)
1